Share on StockTwits

Stock analysts at Canaccord Genuity reduced their target price on shares of Derma Sciences (NASDAQ:DSCI) from $19.00 to $18.00 in a report issued on Friday. Canaccord Genuity’s target price points to a potential upside of 99.56% from the stock’s previous close.

Shares of Derma Sciences (NASDAQ:DSCI) opened at 9.02 on Friday. Derma Sciences has a 52-week low of $8.45 and a 52-week high of $15.51. The stock has a 50-day moving average of $10.55 and a 200-day moving average of $11.32. The company’s market cap is $227.1 million.

Derma Sciences (NASDAQ:DSCI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.46) by $0.12. On average, analysts predict that Derma Sciences will post $-1.89 earnings per share for the current fiscal year.

Derma Sciences, Inc (NASDAQ:DSCI), is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.